Pseudoerythromycin A enol ether

• UNSPSC Description:

  Pseudoerythromycin A enol ether (LY267108) is a degradation product of Erythromycin. Pseudoerythromycin A enol ether has no significant antimicrobial activity[1][2].

• Target Antigen:

  Drug Metabolite

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/pseudoerythromycin-a-enol-ether.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@](OC([C@@H]([C@]1([H])[C@](C)(O)[C@H](O)CC)C)=C2C)(C2)[C@@H]([C@H]([C@@H]([C@H](C(O1)=O)C)O[C@H](O[C@H]3C)C[C@](C)([C@H]3O)OC)C)O[C@H](O[C@@H]4C)[C@@H]([C@H](C4)N(C)C)O

• Molecular Weight:

  715.91

• References & Citations:

  [1]Pendela M, et al. Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation. Anal Bioanal Chem. 2012;402(2):781-790.|[2]Greenwood B, et al. Effects of LY267108, an erythromycin analogue derivative, on lower esophageal sphincter function in the cat. Gastroenterology. 1994;106(3):624-628.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  105882-69-7